Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTNR0UQ)

• DTT Name: Lysine-specific histone demethylase 1 (LSD) DTT Info
• Gene Name: KDM1A

Molecule-Related Drug & Molecule List

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[1]
IMG-7289	DML9AVG	Acute myeloid leukaemia	2A60	Phase 2	[1]
ORY-2001	DMYM0UY	Alzheimer disease	8A20	Phase 2	[2]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[3]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[1]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[4]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[5]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[6]

69 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aryl cyclopropylamine derivative 3	DMZECH7	N. A.	N. A.	Patented	[7]
Aryl cyclopropylamine derivative 4	DM0C1ZO	N. A.	N. A.	Patented	[7]
Aryl cyclopropylamine derivative 5	DM6CK7J	N. A.	N. A.	Patented	[7]
Benzenamine derivative 1	DM6PMZC	N. A.	N. A.	Patented	[7]
Benzenamine derivative 2	DMDZ7QS	N. A.	N. A.	Patented	[7]
Benzenamine derivative 3	DM8UXZ3	N. A.	N. A.	Patented	[7]
Benzenamine derivative 4	DMQT7HV	N. A.	N. A.	Patented	[7]
Cyclic peptide derivative 1	DM78NOU	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 1	DMXN361	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 10	DMZ5WN8	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 11	DMMJ0YN	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 12	DMV4I0K	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 13	DMXNVD4	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 3	DM6E9L4	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 4	DMOCF4Y	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 5	DM5BCGD	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 6	DMB2RKC	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 7	DM3X4PJ	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 8	DMA89WQ	N. A.	N. A.	Patented	[7]
Cyclopropylamine derivative 9	DMX7YAL	N. A.	N. A.	Patented	[7]
Heteroaryl-cyclopropylamine derivative 1	DMRF58Q	N. A.	N. A.	Patented	[7]
Heteroaryl-cyclopropylamine derivative 2	DM9NE5T	N. A.	N. A.	Patented	[7]
Heteroaryl-cyclopropylamine derivative 3	DMH9EQ1	N. A.	N. A.	Patented	[7]
Heteroaryl-cyclopropylamine derivative 4	DMMU01R	N. A.	N. A.	Patented	[7]
N-(2-phenylcyclopropyl) amino acid derivative 1	DMH7T8C	N. A.	N. A.	Patented	[7]
N-(2-phenylcyclopropyl) amino acid derivative 2	DM6YV3O	N. A.	N. A.	Patented	[7]
N-(2-phenylcyclopropyl) amino acid derivative 3	DMFBRSL	N. A.	N. A.	Patented	[7]
N6-cyclopropyllydine derivative 1	DMRHVWA	N. A.	N. A.	Patented	[7]
PMID25399762-Compound-Table 6-10	DM4UM03	N. A.	N. A.	Patented	[8]
PMID25399762-Compound-Table 6-11	DMYGTU2	N. A.	N. A.	Patented	[8]
PMID25399762-Compound-Table 6-12	DMZ07RP	N. A.	N. A.	Patented	[8]
PMID25399762-Compound-Table 6-13	DM6LR42	N. A.	N. A.	Patented	[8]
PMID25399762-Compound-Table 6-14	DMZHB9Y	N. A.	N. A.	Patented	[8]
PMID25399762-Compound-Table 6-15	DMCHWSF	N. A.	N. A.	Patented	[8]
PMID25399762-Compound-Table 6-9	DMDWIPG	N. A.	N. A.	Patented	[8]
PMID27019002-Compound-13	DMD0HAT	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-16	DMZ9T8H	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-17	DM7JASU	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-20a	DMRX748	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-20b	DMYRV8I	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-21a	DMC6AF2	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-21b	DMMC31N	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-21c	DMWZOKP	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-28	DM1R6GA	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-28a	DM954C8	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-31a	DMRWGHN	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-31b	DMJ1K4Y	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-37a	DMMB6XC	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-37b	DMCIT5A	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-41	DMVLXRB	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-42a	DM42VUQ	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-42b	DMHJBRO	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-43a	DMMOVGU	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-43b	DMIMFND	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-43c	DM72TBJ	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-44	DM5HUCR	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-45	DM3G6YV	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-46	DMQPU7K	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-47	DMRLWP9	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-48	DMIO8J3	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-49	DMP6WCX	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-50	DM4D75L	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-7	DMB0S52	N. A.	N. A.	Patented	[7]
Pyrimidine derivative 16	DM3GYPD	N. A.	N. A.	Patented	[7]
Pyrimidine derivative 17	DM7YA9Z	N. A.	N. A.	Patented	[7]
Pyrimidine derivative 18	DMIZTKS	N. A.	N. A.	Patented	[7]
Tarnylcypromine derivative 1	DMQKOMR	N. A.	N. A.	Patented	[7]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[7]
Tarnylcypromine derivative 3	DMKJOMC	N. A.	N. A.	Patented	[7]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK-LSD1	DMHJU7A	Discovery agent	N.A.	Investigative	[9]
NCL-1	DMH1BVG	Discovery agent	N.A.	Investigative	[10]
OG-L002	DM0PMKW	Discovery agent	N.A.	Investigative	[11]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
• [3] Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
• [4] A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
• [5] Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
• [6] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [7] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
• [8] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2669).
• [10] Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem. 2011 Jun 15;19(12):3702-8.
• [11] A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013 Feb 5;4(1):e00558-12.